Alembic Pharmaceuticals Limited (BOM:533573)

Alembic Pharmaceuticals Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	6,748	5,834	6,158	3,420	5,209
Depreciation & Amortization	3,186	2,786	2,727	2,754	2,868
Other Amortization	-	-	-	984.4	801.3
Loss (Gain) From Sale of Assets	21.7	-32.6	-17	47	-5.4
Loss (Gain) From Sale of Investments	8.4	-4	-27.6	-1.4	-
Loss (Gain) on Equity Investments	-2.4	-8.7	9.8	309.2	-52.8
Provision & Write-off of Bad Debts	9.3	34.6	53.6	-	73
Other Operating Activities	425.3	1,484	84.8	301.7	303.6
Change in Accounts Receivable	77.3	-3,950	390.5	-2,229	-4,696
Change in Inventory	-2,225	-6,446	-1,683	1,344	-1,236
Change in Accounts Payable	-492.7	1,462	560.4	-281.7	366.7
Change in Other Net Operating Assets	72.2	-279.1	-224.6	590.5	1,892
Operating Cash Flow	7,827	879.7	8,032	7,240	5,524
Operating Cash Flow Growth	789.77%	-89.05%	10.95%	31.07%	-62.26%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-4,346	-5,636	-3,275	-4,434	-4,256
Sale of Property, Plant & Equipment	21.7	97.7	115.6	18.7	13.9
Sale (Purchase) of Intangibles	-602.6	-	-	-	-
Investment in Securities	-	-50	-	-70	476.8
Other Investing Activities	-133.5	-95.6	-47	9.5	46
Investing Cash Flow	-5,061	-5,684	-3,206	-4,476	-3,720

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	230.4	7,651	-	2,059	4,300
Long-Term Debt Issued	1,423	-	-	-	-
Total Debt Issued	1,653	7,651	-	2,059	4,300
Short-Term Debt Repaid	-	-	-2,054	-	-
Long-Term Debt Repaid	-244.3	-265.6	-258.2	-2,231	-3,202
Total Debt Repaid	-244.3	-265.6	-2,312	-2,231	-3,202
Net Debt Issued (Repaid)	1,409	7,386	-2,312	-172.3	1,098
Common Dividends Paid	-2,162	-2,162	-1,573	-1,966	-2,752
Other Financing Activities	-884.3	-786.3	-493.9	-481.7	-519.7
Financing Cash Flow	-1,638	4,437	-4,379	-2,620	-2,174

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Miscellaneous Cash Flow Adjustments	0.1	-	0.1	-0.1	-
Net Cash Flow	1,129	-367.3	447.3	143.9	-369.7

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	3,481	-4,757	4,757	2,805	1,267
Free Cash Flow Growth	-	-	69.58%	121.40%	-84.24%
Free Cash Flow Margin	4.74%	-7.13%	7.64%	4.96%	2.39%
Free Cash Flow Per Share	17.71	-24.20	24.20	14.27	6.45
Levered Free Cash Flow	203.49	-7,272	2,198	504.46	-324.73
Unlevered Free Cash Flow	788.68	-6,780	2,549	818.03	-213.91

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	881.4	785.9	493.7	497	519.2
Cash Income Tax Paid	1,037	714	198.5	607	1,234
Change in Working Capital	-2,568	-9,214	-956.5	-575.6	-3,673

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 21, 2026

Data Sources Report a data error